United Therapeutics Corporation reported that its Phase 3 TETON‑1 study of nebulized Tyvaso in patients with idiopathic pulmonary fibrosis met its primary efficacy endpoint, showing a 130.1 mL improvement in absolute forced vital capacity (FVC) at 52 weeks versus placebo. The Hodges‑Lehmann estimate of 130.1 mL, with a 95 % confidence interval of 82.2 to 178.1 mL, represents the largest absolute FVC gain reported in an IPF trial to date and exceeds the 95.6 mL improvement observed in the earlier TETON‑2 study.
The TETON‑1 trial enrolled 598 patients across the United States and Canada, ran for 52 weeks, and completed enrollment in January 2025. Integrated analysis of TETON‑1 and TETON‑2 yielded a 111.8 mL absolute FVC improvement, confirming the consistency of the treatment effect across geographic regions and patient subgroups, including those receiving background antifibrotic therapy, smokers, and patients on supplemental oxygen. Secondary endpoints, such as time to first clinical worsening event, also reached statistical significance, while overall survival favored Tyvaso, though the difference did not reach significance.
United Therapeutics estimates that approval of nebulized Tyvaso for IPF could unlock a $5–10 billion opportunity, expanding the drug’s use beyond pulmonary arterial hypertension. The company plans to submit a supplemental New Drug Application to the FDA by the end of summer 2026, positioning Tyvaso as a potential new standard of care for IPF if approved.
The trial announcement comes amid a period of strong financial performance for United Therapeutics. In the fourth quarter of 2024, the company posted record revenue of $2.88 billion, a 24 % increase over 2023, and net income of $1.195 billion. The first quarter of 2025 saw total revenues of $794.4 million, up 17 % year‑over‑year. Management highlighted the clinical success, noting that the results “represent a profound step forward for people living with IPF” and that the data “provide a compelling body of evidence for nebulized Tyvaso’s differentiated direct lung delivery combined with multimodal activity across fibrotic, vascular, and inflammatory pathways that are not currently addressed by existing therapies.”
Tyvaso would become the first inhaled anti‑fibrotic therapy for IPF, entering a market currently served by oral agents pirfenidone and nintedanib. The differentiated delivery route and multimodal mechanism could offer a therapeutic advantage, potentially improving patient adherence and outcomes. The positive TETON‑1 results therefore not only support a new indication but also strengthen United Therapeutics’ competitive positioning in the broader respiratory therapeutics portfolio.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.